Abstract
Accumulating evidence has suggested the involvement of oxidative stress in the pathogenesis of Alzheimer’s disease (AD). The main endogenous antioxidant, glutathione (GSH), has been shown to decline with ageing and in several age-related degenerative diseases, including AD. Potential options for replenishing GSH levels as a therapeutic target to treat these conditions include the administration of GSH itself, and low toxicity forms of the limiting amino acid for GSH synthesis; cysteine. However, passive GSH uptake is limited due to an unfavourable concentration gradient between the plasma and cytosol. Similarly, cysteine prodrugs have demonstrated limited efficacy to elevate depleted GSH levels in several in vivo and in vitro models of disease. It has been suggested that the decline in GSH levels in AD, may be associated with down regulation of GSH homeostasis rather than substrate limitation. Cellular GSH homeostasis is regulated by non-allosteric feedback inhibition exerted by GSH on glutamate cysteine ligase (GCL), which is responsible for the synthesis of the GSH precursor γ-glutamylcysteine (GGC). In conditions involving down regulated GSH homeostasis, GGC serves as a crucialrate-limiting substrate for GSH synthetase, the main enzyme responsible for condensing glycine with GGC to form the final thiol tripeptide, GSH. In this review, we focus on the therapeutic potential of GGC to elevate cellular GSH levels. We also discuss the efficacy of GGC prodrugs which would be taken up and converted by the unregulated GS to GSH, and the administration of modified GSH compounds, such as GSH esters that could potentially overcome the concentration gradient that prohibits passive GSH uptake, in AD.
Keywords: Alzheimer’s disease, antioxidants, dementia, glutathione, oxidative stress.
Current Alzheimer Research
Title:Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease
Volume: 12 Issue: 4
Author(s): Nady Braidy, Martin Zarka, Jeffrey Welch and Wallace Bridge
Affiliation:
Keywords: Alzheimer’s disease, antioxidants, dementia, glutathione, oxidative stress.
Abstract: Accumulating evidence has suggested the involvement of oxidative stress in the pathogenesis of Alzheimer’s disease (AD). The main endogenous antioxidant, glutathione (GSH), has been shown to decline with ageing and in several age-related degenerative diseases, including AD. Potential options for replenishing GSH levels as a therapeutic target to treat these conditions include the administration of GSH itself, and low toxicity forms of the limiting amino acid for GSH synthesis; cysteine. However, passive GSH uptake is limited due to an unfavourable concentration gradient between the plasma and cytosol. Similarly, cysteine prodrugs have demonstrated limited efficacy to elevate depleted GSH levels in several in vivo and in vitro models of disease. It has been suggested that the decline in GSH levels in AD, may be associated with down regulation of GSH homeostasis rather than substrate limitation. Cellular GSH homeostasis is regulated by non-allosteric feedback inhibition exerted by GSH on glutamate cysteine ligase (GCL), which is responsible for the synthesis of the GSH precursor γ-glutamylcysteine (GGC). In conditions involving down regulated GSH homeostasis, GGC serves as a crucialrate-limiting substrate for GSH synthetase, the main enzyme responsible for condensing glycine with GGC to form the final thiol tripeptide, GSH. In this review, we focus on the therapeutic potential of GGC to elevate cellular GSH levels. We also discuss the efficacy of GGC prodrugs which would be taken up and converted by the unregulated GS to GSH, and the administration of modified GSH compounds, such as GSH esters that could potentially overcome the concentration gradient that prohibits passive GSH uptake, in AD.
Export Options
About this article
Cite this article as:
Braidy Nady, Zarka Martin, Welch Jeffrey and Bridge Wallace, Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease, Current Alzheimer Research 2015; 12 (4) . https://dx.doi.org/10.2174/1567205012666150302160308
DOI https://dx.doi.org/10.2174/1567205012666150302160308 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanoparticles Mediated Target-specific Drug Delivery in Prostate
Cancer: An In-depth Review
Current Medicinal Chemistry The Physiological/Pathophysiological Significance of Vitamin D in Cancer, Cardiovascular Disorders and Beyond
Current Drug Metabolism Role of P-Glycoprotein in the Intestinal Absorption of Tanshinone IIA, a Major Active Ingredient in the Root of Salvia miltiorrhiza Bunge
Current Drug Metabolism An Updated Portrait of Pathogenesis, Molecular Markers and Signaling Pathways of Hepatocellular Carcinoma
Current Pharmaceutical Design Multivariate Calibration Applied to the Simultaneous Spectrophotometric Determination of Ascorbic Acid, Tyrosine and Epinephrine in Pharmaceutical Formulation and Biological Fluids
Current Analytical Chemistry Ethosomal Hydrogel of Raloxifene HCl: Statistical Optimization & Ex Vivo Permeability Evaluation Across Microporated Pig Ear Skin
Current Drug Delivery Mitochondria-Targeted Antioxidant Peptide SS31 Protects the Retinas of Diabetic Rats
Current Molecular Medicine Dendrogenin A: A Mammalian Metabolite of Cholesterol with Tumor Suppressor and Neurostimulating Properties
Current Medicinal Chemistry Novel Thiourea Derivatives Bearing Sulfonamide Moiety as Anticancer Agents Through COX-2 Inhibition
Anti-Cancer Agents in Medicinal Chemistry Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Current Medicinal Chemistry Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology Targeting the Expression of Anti-Apoptotic Proteins by Antisense Oligonucleotides
Current Drug Targets Protein Microarrays for Studies of Drug Mechanisms and Biomarker Discovery in the Era of Systems Biology
Current Pharmaceutical Design Topical Application of <i>In Vitro</i> Transcribed mRNA to the Airways as a Novel Gene Therapy Approach for the Treatment of Cystic Fibrosis
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Recent Trends in the Pharmacological Activity of Isoprenyl Phenolics
Current Medicinal Chemistry Current Understanding of Epigenetics Driven Therapeutic Strategies in Colorectal Cancer Management
Endocrine, Metabolic & Immune Disorders - Drug Targets Bioactivity of Chitosan and Its Derivatives
Current Organic Chemistry Recent Advances in Medicinal Applications of Coinage-Metal (Cu and Ag) N-Heterocyclic Carbene Complexes
Current Topics in Medicinal Chemistry Cell Penetrating Peptides for Tumor Targeting
Current Pharmaceutical Biotechnology Lecithin (Phosphatidylcholine): Healthy Dietary Supplement or Dangerous Toxin?
The Natural Products Journal